

# Prognostic Value of Fibrinogen-to-Albumin Ratio in Coronary Three-Vessel Disease [Letter]

Yanli Guo<sup>1</sup>, Yuechou Nong<sup>2</sup>

<sup>1</sup>Yuncheng Vocational and Technical University, Yuncheng, Shanxi, 044000, People's Republic of China; <sup>2</sup>Department of Endocrinology and Metabolism, The Guangxi Academy of Medical Sciences and the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, 530021, People's Republic of China

Correspondence: Yuechou Nong, Email [yuechou\\_gx@163.com](mailto:yuechou_gx@163.com)

## Dear editor

We are interested in the recently published research article<sup>1</sup> entitled “Prognostic Value of Fibrinogen-to-Albumin Ratio in Coronary Three-Vessel Disease” in the Journal of Inflammation Research. We appreciate and congratulate the novel research work conducted by the Li X. team.

The authors aimed to assess the predictive value of the fibrinogen-to-albumin ratio (FAR) in patients with coronary three-vessel disease (TVD) and major adverse cardiac and cerebrovascular events (MACCEs). They conducted a retrospective cohort study using various methods, including receiver operating characteristic (ROC) curve analysis, multivariate Cox regression analysis, concordance index (C-index), net reclassification index (NRI), and integrated discrimination improvement (IDI) assessment. The results showed a significant positive association between FAR and MACCEs. The C-index was 0.72 ( $p < 0.001$ ), the value of NRI was 0.3778 ( $p < 0.001$ ), and the value of IDI was 0.0098 ( $p < 0.001$ ) for those with FAR. Additionally, the inclusion of FAR in the traditional model significantly improved the discrimination and risk reclassification ability for all-cause mortality and MACCEs, respectively. The authors concluded that a higher level of FAR was associated with all-cause mortality and MACCE among patients with TVD, and FAR could improve the predictive performance of traditional risk factors for TVD patients.

We acknowledge the validity of the research findings, but we have identified specific concerns that need attention. Firstly, the lack of data on an appropriate therapeutic schedule for diabetes, occurrences of hypoglycemia events, and HbA1c-related blood glucose control goals is a significant concern. The baseline data showed that about 40% of the participants were elderly aged  $\geq 60$ , and the average fasting blood glucose is about 7.5 mmol/l, indicating relatively strict blood glucose control goals accompanied by hypoglycemic events caused by insulin or sulfonylureas. According to an expert consensus,<sup>2</sup> strict blood glucose control should be avoided for diabetes patients in the ICU and elderly with chronic severe cardiovascular complications, which can lead to a fatal hypoglycemic event. Despite these suggestions, overtreatment is still common in daily clinical practice among these patients, especially those who use insulin or sulfonylurea drugs. Additionally, according to guideline,<sup>3</sup> such patients with diabetes mellitus recruited in the current research should have started the SGLT2i and/or GLP-1RA program, which can significantly prevent/reduce MACCEs in the real-world clinical practice, putting up confounding factors for FAR. Secondly, the lack of thyroid function assessment data is another concern. Even subtle changes in circulating thyroid hormones, such as subclinical hypothyroidism/hyperthyroidism and low triiodothyronine syndrome, can affect the cardiovascular system. Thyroid hormones have receptors in myocardial and vascular endothelial tissues, and potential mechanisms linking these conditions include dyslipidemia, endothelial dysfunction, blood pressure changes, and direct effects of thyroid hormones on the myocardium.<sup>4</sup> Multiple studies support the association between abnormal thyroid function during an acute myocardial infarction (MI) and subsequent adverse cardiovascular outcomes. Additionally, experimental studies have demonstrated that maintaining normal thyroid hormone levels can effectively reduce the risk of arrhythmia and right heart failure in diabetic patients. Therefore, thyroid function status is also a confounding factor for FAR.

To summarize, addressing these concerns will improve the reliability of the research findings and their clinical application prospects in routine clinical practice.

## Disclosure

The authors report no conflicts of interest in this communication.

## References

1. Li X, Wang Z, Zhu Y, et al. Prognostic value of fibrinogen-to-albumin ratio in coronary three-vessel disease. *J Inflamm Res.* 2023;16:5767–5777. doi:10.2147/JIR.S443282
2. International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. *Lancet Diabetes Endocrinol.* 2019;7(5):385–396. doi:10.1016/S2213-8587(18)30315-2
3. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care.* 2022;45(11):2753–2786. doi:10.2337/dci22-0034
4. Jabbar A, Pingitore A, Pearce SHS, et al. Thyroid hormones and cardiovascular disease. *Nat Rev Cardiol.* 2017;14(1):39–55. doi:10.1038/nrcardio.2016.174

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Journal of Inflammation Research 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Journal of Inflammation Research editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Journal of Inflammation Research

Dovepress

Publish your work in this journal

The Journal of Inflammation Research is an international, peer-reviewed open-access journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation including original research, reviews, symposium reports, hypothesis formation and commentaries on: acute/chronic inflammation; mediators of inflammation; cellular processes; molecular mechanisms; pharmacology and novel anti-inflammatory drugs; clinical conditions involving inflammation. The manuscript management system is completely online and includes a very quick and fair peer-review system. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/journal-of-inflammation-research-journal>

<https://doi.org/10.2147/JIR.S455664>